Premiere Date: March 20, 2018
Expiration Date: July 20, 2019
This activity offers CE credits for:
1. Physicians (CME)
All other clinicians either will receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.
To understand the role of stress in the manifestation of depressive symptoms.
At the end of this CE activity, participants should be able to:
• Describe the brain circuits associated with depressive symptom clusters
• Identify the multiple functions associated with reward systems (eg, anticipatory, consummatory)
• Explain how the frontal cortex affects cognition in depression
This continuing medical education activity is intended for psychiatrists, psychologists, primary care physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve their care for patients with mental health disorders.
CME Credit (Physicians):This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Outfitters, LLC, and Psychiatric Times. CME Outfitters, LLC, is accredited by the ACCME to provide continuing medical education for physicians.
CME Outfitters designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners and Physician Assistants: AANPCP and AAPA accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer-review process.
The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Serge Campeau, PhD, has no disclosures to report.
Bruce S. McEwen, PhD, (peer/content reviewer) has no disclosures to report.
Applicable Psychiatric Times staff and CME Outfitters staff have no disclosures to report.
UNLABELED USE DISCLOSURE
Faculty of this CME/CE activity may include discussion of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, and the faculty do not endorse the use of any product outside of the FDA-labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767)
1. Austin J. Psychiatric Genetic Counseling. https://www.youtube.com/watch?v=PqnxqMnPk_g. Accessed February 6, 2018.
2. Resta R, Biesecker BB, Bennett RL for the National Society of Genetic Counselors’ Definition Task Force. A new definition of genetic counseling: National Society of Genetic Counselors’ task force report. J Genet Couns. 2006:15:77-83.
3. Veach PM, Bartels DM, Leroy BS. Coming full circle: a reciprocal-engagement model of genetic counseling practice. J Genet Couns. 2007:16:713-728.
4. Inglis A, Koehn D, McGillivray B, et al. Evaluating a unique, specialist psychiatric genetic counseling clinic: uptake and impact. Clin Genet. 2015;87:218-224.
5. Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86:749-764.
6. Butcher N, Fung WLA, Fitzpatrick L, et al. Response to clozapine in a clinically identifiable subtype of schizophrenia: 22q11.2 deletions mediate side effect risk and dosage. Br J Psychiatry. 2015:206:484-491.
7. Austin J, Semaka A, Hadjipavlou G. Conceptualizing genetic counseling as psychotherapy in the era of genomic medicine. J Genet Coun. 2014;23:903-909.
8. Hippman C, Ringrose A, Inglis A, et al. A pilot randomized clinical trial of the impact of genetic counseling for individuals with serious mental illness. J Clin Psychiatry. 2016;77:e190-e198.
9. Leach E, Morris E, White H, et al. How do physicians decide to refer their patients for psychiatric genetic counseling? A qualitative study of physicians’ practice. J Gene Coun. 2016;25:1235-1242.
10. Peay HL, Austin JC. How to Talk With Families About Genetics and Psychiatric Illness, 1st ed. New York, NY: WW Norton Co; 2011.
11. Inglis A, Morris E, Austin J. Prenatal genetic counseling for psychiatric disorders. Prenat Diag. 2017;37:6-13.
12. Austin J, Peay HL. Applications and limitations of empiric data in provision of recurrence risks for schizophrenia: a practical review for healthcare professionals providing clinical psychiatric genetics consultations. Clin Genet. 2006;70:177-187.
13. Austin JC, Palmer C, Sheidley B, et al. Psychiatric disorders in clinical genetics II: Individualizing recurrence risks for psychiatric disorders. J Gene Coun. 2008;17:18-29.
14. Ryan J, Virani A, Austin J. Ethical issues associated with genetic counseling in the context of adolescent psychiatry. Appl Transl Genom. 2015;5:23-29.